Fiche centre
University Hospitals Plymouth NHS Trust
Plymouth — United Kingdom
Essais liés3clinical trials
VillePlymouthlocalisation
PaysUnited Kingdomlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06553027
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Cladribine (MAVENCLAD®) | SEP | Phase 2/3 | NCT04695080 | ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| BIA 28-6156 | Parkinson | À vérifier | NCT07522606 | Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study | NO_LONGER_AVAILABLE |
| CVN424 75 mg | Parkinson | Phase 3 | NCT06553027 | To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | ACTIVE_NOT_RECRUITING |